A U.S. cannabis company has expressed interest in acquiring Aurora Cannabis Inc., based in Edmonton. Aurora has formed a special committee to review the unsolicited bid from Curaleaf Holdings Inc., which aims to purchase all of Aurora’s shares. Curaleaf envisions creating a global cannabis entity spanning 17 countries in Europe, North America, and other regions.
Despite attempts to engage in private negotiations, Curaleaf decided to go public with its proposal after Aurora’s board declined discussions following a formal letter of intent from Curaleaf’s CEO, Boris Jordan. Curaleaf has offered to pay Aurora shareholders $4 US per share, along with an additional $0.75 US cash for each Aurora share. Aurora acknowledges receiving letters from Curaleaf but disputes the claim of refusing to engage with the offer.
Aurora’s independent director recently communicated with Curaleaf’s CEO, expressing a focus on executing its business plan in the short to medium term. Aurora will establish a special committee to evaluate the proposal and determine its impact on stakeholders. While discussions are ongoing, Aurora will continue operating as usual, with no guarantee of reaching a deal.
Analysts from TD Cowen noted that Curaleaf’s offer undervalues Aurora’s potential, citing Aurora’s market leadership in medical cannabis and strong global presence. Curaleaf believes merging with Aurora would unlock value by combining distribution platforms and manufacturing capabilities. The companies collectively generated over $1.5 billion US in revenue in the past year, with Curaleaf expecting significant cost synergies from the potential takeover.
Curaleaf sees the merger as mutually beneficial, offering Aurora shareholders an opportunity to engage in a diversified global platform and benefit from regulatory developments in the U.S.